Reneo Pharmaceuticals, Inc. (RPHM)

Reneo Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	27.63	19.93	124.66	53.61	17.5
Short-Term Investments	75.33	81.25	23.01	0	7.39
Cash & Cash Equivalents	102.96	101.17	147.67	53.61	24.89
Cash Growth	1.77%	-31.49%	175.44%	115.43%	-
Other Current Assets	3.66	5.18	6.06	1.41	0.52
Total Current Assets	106.62	106.35	153.73	55.03	25.41
Property, Plant & Equipment	0.73	1.75	0.21	0.07	0.08
Other Long-Term Assets	0.08	0.08	0.08	0.13	0.02
Total Long-Term Assets	0.81	1.83	0.29	0.2	0.1
Total Assets	107.44	108.18	154.02	55.22	25.51
Accounts Payable	8.72	1.89	2.02	0.91	0.54
Current Debt	0.33	0.4	0	0	0
Other Current Liabilities	9.13	4.83	4.18	3.67	2.4
Total Current Liabilities	18.18	7.12	6.2	4.58	2.94
Long-Term Debt	0.64	1.06	0	0	0
Other Long-Term Liabilities	0.01	0.03	0.61	0.04	0.04
Total Long-Term Liabilities	0.65	1.09	0.61	0.04	0.04
Total Liabilities	18.83	8.21	6.81	4.62	2.98
Total Debt	0.97	1.46	0	0	0
Debt Growth	-33.49%	-	-	-	-
Retained Earnings	-218.47	-136.68	-84.73	-44.96	-25.49
Comprehensive Income	0.01	-0.04	0.03	0	0
Shareholders' Equity	88.61	99.97	147.21	-42.12	-23.13
Net Cash / Debt	101.99	99.71	147.67	53.61	24.89
Net Cash / Debt Growth	2.29%	-32.48%	175.44%	115.43%	-
Net Cash Per Share	3.32	4.07	8.14	26.43	12.77
Working Capital	88.45	99.23	147.53	50.45	22.47
Book Value Per Share	2.89	4.08	8.11	-20.77	-11.87

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).